|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-11-5
|
|
pubmed:abstractText |
In an effort to improve the results of primary chemotherapy for müllerian malignancies a novel chemotherapy program was piloted that delivered three sequential chemotherapy doublets. The primary endpoints were surgically defined response rates and evaluation of toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
pubmed-author:BerkowitzRR,
pubmed-author:CamposSS,
pubmed-author:ColellaTT,
pubmed-author:Dana Farber-Harvard Cancer Care,
pubmed-author:DuskaLL,
pubmed-author:FullerAA,
pubmed-author:GoreSS,
pubmed-author:Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care,
pubmed-author:LeeHH,
pubmed-author:MatulonisUU,
pubmed-author:RocheMM,
pubmed-author:SeidenM VMV
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
293-8
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:14599858-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14599858-Carboplatin,
pubmed-meshheading:14599858-Combined Modality Therapy,
pubmed-meshheading:14599858-Cystadenocarcinoma, Papillary,
pubmed-meshheading:14599858-Cystadenocarcinoma, Serous,
pubmed-meshheading:14599858-Deoxycytidine,
pubmed-meshheading:14599858-Doxorubicin,
pubmed-meshheading:14599858-Drug Administration Schedule,
pubmed-meshheading:14599858-Endometrial Neoplasms,
pubmed-meshheading:14599858-Fallopian Tube Neoplasms,
pubmed-meshheading:14599858-Female,
pubmed-meshheading:14599858-Genital Neoplasms, Female,
pubmed-meshheading:14599858-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:14599858-Humans,
pubmed-meshheading:14599858-Middle Aged,
pubmed-meshheading:14599858-Mixed Tumor, Mullerian,
pubmed-meshheading:14599858-Ovarian Neoplasms,
pubmed-meshheading:14599858-Peritoneal Neoplasms,
pubmed-meshheading:14599858-Topotecan
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
|
|
pubmed:affiliation |
Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
